Search research articles
Contact Us
Filters
Showing results (11-20 of 19) with videos related to
Page
of 2
Sort By:
You have reached the last page of results.
This site can display upto 19 results.
British Journal of Cancer
|
October 17, 2003
A multicentre phase II trial of bryostatin-1 in patients with advanced renal cancer
S Madhusudan, A Protheroe, D Propper, et al.
The International Journal of Biochemistry & Cell Biology
|
December 6, 2011
Inhibition of MT1-MMP activity using functional antibody fragments selected against its hemopexin domain
B Basu, P Correa de Sampaio, H Mohammed, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 15, 2018
Paclitaxel with or without trametinib or pazopanib in advanced wild-type BRAF melanoma (PACMEL): a multicentre, open-label, randomised, controlled phase II trial
V Urbonas, D Schadendorf, L Zimmer, et al.
Seminars in Oncology
|
September 29, 2018
Rapid disease progression in a patient with mismatch repair-deficient and cortisol secreting adrenocortical carcinoma treated with pembrolizumab
R T Casey, O Giger, I Seetho, et al.
Journal of Plastic, Reconstructive & Aesthetic Surgery : JPRAS
|
September 4, 2019
Current role of sentinel lymph node biopsy in the management of cutaneous melanoma: A UK consensus statement
H Peach, R Board, M Cook, et al.
British Journal of Cancer
|
August 13, 2009
Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: a multicentre randomised phase II study - The UK ABC-01 Study
J W Valle, H Wasan, P Johnson, et al.
British Journal of Cancer
|
July 14, 2011
Sorafenib and dacarbazine as first-line therapy for advanced melanoma: phase I and open-label phase II studies
T Eisen, R Marais, A Affolter, et al.
Gut
|
May 13, 2005
Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours
J K Ramage, A H G Davies, J Ardill, et al.
Gut
|
November 5, 2011
Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs)
John K Ramage, A Ahmed, J Ardill, et al.
Page
of 2
Search research articles
Search
Showing results (11-20 of 19) with videos related to
Sort By:
Page
of 2
You have reached the last page of results.
This site can display upto 19 results.
British Journal of Cancer
|
October 17, 2003
A multicentre phase II trial of bryostatin-1 in patients with advanced renal cancer
S Madhusudan, A Protheroe, D Propper, et al.
The International Journal of Biochemistry & Cell Biology
|
December 6, 2011
Inhibition of MT1-MMP activity using functional antibody fragments selected against its hemopexin domain
B Basu, P Correa de Sampaio, H Mohammed, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 15, 2018
Paclitaxel with or without trametinib or pazopanib in advanced wild-type BRAF melanoma (PACMEL): a multicentre, open-label, randomised, controlled phase II trial
V Urbonas, D Schadendorf, L Zimmer, et al.
Seminars in Oncology
|
September 29, 2018
Rapid disease progression in a patient with mismatch repair-deficient and cortisol secreting adrenocortical carcinoma treated with pembrolizumab
R T Casey, O Giger, I Seetho, et al.
Journal of Plastic, Reconstructive & Aesthetic Surgery : JPRAS
|
September 4, 2019
Current role of sentinel lymph node biopsy in the management of cutaneous melanoma: A UK consensus statement
H Peach, R Board, M Cook, et al.
British Journal of Cancer
|
August 13, 2009
Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: a multicentre randomised phase II study - The UK ABC-01 Study
J W Valle, H Wasan, P Johnson, et al.
British Journal of Cancer
|
July 14, 2011
Sorafenib and dacarbazine as first-line therapy for advanced melanoma: phase I and open-label phase II studies
T Eisen, R Marais, A Affolter, et al.
Gut
|
May 13, 2005
Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours
J K Ramage, A H G Davies, J Ardill, et al.
Gut
|
November 5, 2011
Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs)
John K Ramage, A Ahmed, J Ardill, et al.
Page
of 2